Pulmonx Corporation Stock 12‑Month Price Target Raised to $3.7, Implies 87% Upside

Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.

Original reporting
Published Oct 28, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pulmonx Corporation Stock 12‑Month Price Target Raised to $3.7, Implies 87% Upside — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst consensus remains a Buy, with three Buys and two Holds, reinforcing the positive outlook.

02

Market read

The price‑target upgrade provides a fresh catalyst for a small‑cap stock, offering a potential short‑term trade idea.

03

What to watch

Potential regulatory or reimbursement hurdles for Pulmonx's products could temper upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Pulmonx is a micro‑cap medical device company focused on lung disease treatments.

Market effects

May lift sentiment in the pulmonary medical devices niche.

Limited to US small‑cap investors.

Low

Counterpoint

Target raises for micro‑caps can be premature; price may stall if execution risks materialize.

Key entities

  • Pulmonx Corporation

    US‑listed medical device firm (ticker PNLX).

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.